Cargando…

Development of novel salicylic acid–donepezil–rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer’s disease

Alzheimer’s disease (AD) is a chronic, progressive brain degenerative disease that is common in the elderly. So far, there is no effective treatment. The multi-target-directed ligands (MTDLs) strategy has been recognised as the most promising approach due to the complexity of the pathogenesis of AD....

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yi, He, Ying, Teng, Xue, Mi, Jing, Yang, Jing, Wei, Rongrui, Liu, Wenmin, Ma, Qinge, Tan, Zhenghuai, Sang, Zhipei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327518/ https://www.ncbi.nlm.nih.gov/pubmed/37414563 http://dx.doi.org/10.1080/14756366.2023.2231661

Ejemplares similares

Development of naringenin-O-alkylamine derivatives as multifunctional agents for the treatment of Alzheimer’s disease
por: Yang, Jing, et al.
Publicado: (2022)

Donepezil structure-based hybrids as potential multifunctional anti-Alzheimer’s drug candidates
por: Piemontese, Luca, et al.
Publicado: (2018)

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis
por: Hansen, Richard A, et al.
Publicado: (2008)

MARK4 Inhibited by AChE Inhibitors, Donepezil and Rivastigmine Tartrate: Insights into Alzheimer’s Disease Therapy
por: Shamsi, Anas, et al.
Publicado: (2020)

Effect of Donepezil, Tacrine, Galantamine and Rivastigmine on Acetylcholinesterase Inhibition in Dugesia tigrina
por: Bezerra da Silva, Cristiane, et al.
Publicado: (2016)

QT interval prolongation and Torsades de Pointes with donepezil, rivastigmine and galantamine
por: Malone, Katie, et al.
Publicado: (2020)

The recent development of donepezil structure-based hybrids as potential multifunctional anti-Alzheimer's agents: highlights from 2010 to 2020
por: Kareem, Rzgar Tawfeeq, et al.
Publicado: (2021)

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
por: Li, Dan-Dan, et al.
Publicado: (2019)

Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6 Genotype-Dependent Metabolism of Donepezil
por: Ortner, Marion, et al.
Publicado: (2020)

Donepezil and Rivastigmine: Pharmacokinetic Profile and Brain-targeting After Intramuscular Administration in Rats
por: Karasova, Jana Zdarova, et al.
Publicado: (2020)

Drug Persistency Patterns for Patients Treated With Rivastigmine or Donepezil in Usual Care Settings
por: Mauskopf, Josephine A., et al.
Publicado: (2005)

Two cases of Alzheimer’s disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil
por: Kimura, Takemi, et al.
Publicado: (2013)

Design, synthesis, and evaluation of chalcone-Vitamin E-donepezil hybrids as multi-target-directed ligands for the treatment of Alzheimer’s disease
por: Sang, Zhipei, et al.
Publicado: (2021)

Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer’s disease therapy
por: Pachón-Angona, Irene, et al.
Publicado: (2019)

Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats
por: Papp, Mariusz, et al.
Publicado: (2016)

Design, synthesis and evaluation of quinoline-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer’s disease
por: Chen, Hongsong, et al.
Publicado: (2023)

Rivastigmine in the treatment of Alzheimer’s disease: an update
por: Onor, Maria Luisa, et al.
Publicado: (2007)

Rivastigmine in the treatment of patients with Alzheimer’s disease
por: Müller, Thomas
Publicado: (2007)

Novel Hydroxytyrosol-Donepezil Hybrids as Potential Antioxidant and Neuroprotective Agents
por: Costanzo, Paola, et al.
Publicado: (2021)

Multifunctional Donepezil Analogues as Cholinesterase and BACE1 Inhibitors
por: Green, Keith D., et al.
Publicado: (2018)

Claulansine F–Donepezil Hybrids as Anti-Alzheimer’s Disease Agents with Cholinergic, Free-Radical Scavenging, and Neuroprotective Activities
por: Zang, Yingda, et al.
Publicado: (2021)

Rivastigmine in Alzheimer’s disease: Cognitive function and quality of life
por: Annicchiarico, Roberta, et al.
Publicado: (2007)

Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
por: Wentrup, Andreas, et al.
Publicado: (2009)

Cholinesterase inhibitors, donepezil and rivastigmine, attenuate spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats
por: Gawel, Kinga, et al.
Publicado: (2016)

Design, synthesis, and evaluation of novel O-alkyl ferulamide derivatives as multifunctional ligands for treating Alzheimer’s disease
por: Zhu, Gaofeng, et al.
Publicado: (2022)

Influence of Rivastigmine transdermal on butyrylcholinesterase levels in patients with Alzheimer's disease
por: dos Santos, Gustavo Alves Andrade, et al.
Publicado: (2011)

Transdermal donepezil on the treatment of Alzheimer’s disease
por: Sozio, Piera, et al.
Publicado: (2012)

Design, Synthesis, In Silico Studies and In Vitro Evaluation of New Indole- and/or Donepezil-like Hybrids as Multitarget-Directed Agents for Alzheimer’s Disease
por: Angelova, Violina T., et al.
Publicado: (2023)

Quercetin-1,2,3-Triazole Hybrids as Multifunctional Anti-Alzheimer’s Agents
por: Carreiro, Elisabete P., et al.
Publicado: (2023)

A Novel Multifunctional 5,6-Dimethoxy-Indanone-Chalcone-Carbamate Hybrids Alleviates Cognitive Decline in Alzheimer’s Disease by Dual Inhibition of Acetylcholinesterase and Inflammation
por: Liu, Chan, et al.
Publicado: (2022)

Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study
por: Tsuno, Norifumi, et al.
Publicado: (2019)

Esophagectasis Related to Rivastigmine
por: Sasaki, Osamu, et al.
Publicado: (2019)

Novel Donepezil–Arylsulfonamide Hybrids as Multitarget-Directed Ligands for Potential Treatment of Alzheimer’s Disease
por: Queda, Fausto, et al.
Publicado: (2021)

Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice
por: Seibert, Johannes, et al.
Publicado: (2012)

Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
por: Ray, Balmiki, et al.
Publicado: (2020)

Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease
por: Shimura, Hideki, et al.
Publicado: (2021)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
por: Siddique, Yasir Hasan, et al.
Publicado: (2022)

Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases
por: Pooladgar, Parham, et al.
Publicado: (2022)

New Hybrid Compounds Incorporating Natural Products as Multifunctional Agents against Alzheimer’s Disease
por: Ciccone, Lidia, et al.
Publicado: (2023)

Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer’s disease
por: Ismail, Manal Fouad, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_hc0h3jgkhb60js0gj75if66qvc